ArticleMedicine2026
Risk of hepatitis B reactivation in COVID-19 patients receiving corticosteroid therapy: A retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 and HBV are significant public health issues, and managing their co-infection remains unclear. Corticosteroid therapy improves survival in severe COVID-19 but may increase the risk of HBV reactivation (HBVr). Evidence regarding the incidence and outcomes of HBVr in COVID-19 patients remains limited. This study aimed to investigate the frequency, determinants, and clinical consequences of HBVr among COVID-19 patients with current or past HBV infection treated with corticosteroids. This retrospective study evaluated adult patients with COVID-19 and evidence of HBV infection hospitalized between March 2020 and January 2022 at a tertiary center, where 13,673 individuals were screened during the study period. Demographics, corticosteroid use, laboratory findings, HBV DNA results, and outcomes were analyzed. HBVr was defined according to the criteria outlined in current international guidelines. Out of 13,673 hospitalized COVID-19 patients, 145 (125 HBsAg-positive and 20;anti-HBcIgG-positive) were identified as having HBV exposure. Corticosteroids were administered to 75 patients (51.7%) with a median cumulative dose of 520 (240-1400) mg and duration of 6 (4-10) days. HBVr occurred in 7 patients, all HBsAg-positive; 2 developed hepatic failure and died. Patients with HBVr had significantly higher cumulative corticosteroid doses (p=.021) and longer durations of therapy (p=.007) compared with those without reactivation. Five patients received nucleos(t)ide analogues with subsequent viral suppression. COVID-19 patients with chronic HBV infection, particularly those receiving corticosteroids, are at increased risk of HBVr and poor outcomes. Based on our findings, HBV screening and consideration of antiviral prophylaxis should be routine prior to corticosteroid therapy, particularly in regions with intermediate-to-high HBV prevalence, since HBVr may occur even with short-term corticosteroid exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.